The EC approval also now means that Libtayo can be used to treat certain patients across four types of cancer within the European Union: advanced squamous cell carcinoma (SCC), advanced basal cell ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

But "cancer drugs offering low or no added benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022 and ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

today announced that Ig - Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data ...

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.

Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron’s ability to develop blockbuster drugs. Regeneron appears ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands ...

Philogen SpA reported a significant increase in its full-year 2024 revenues, reaching €77.5 million, a threefold rise compared to the previous year. Despite the impressive financial performance ...